With a $215 million investment in the U.S.’s 2016 budget, precision medicine is clearly the future of healthcare. It’s critical in accelerating medical discoveries and providing clinicians with new tools, knowledge, and therapies to select appropriate treatments for individual patients.

Interpreta CEO, Dr. Ahmed Ghouri, was one of the experts interviewed by PharmaVOICE for its “Year in Preview 2016” issue and spoke about precision medicine’s impact on companies’ research and development strategies in the new year. According to Dr. Ghouri, “Companies need to have a combination of high-performance computing, knowledge representation, and data science to gain better insights into diseases so that they can make a difference to patients.”